Avidity Biosciences Future Growth
Future criteria checks 2/6
Avidity Biosciences is forecast to grow earnings and revenue by 29.9% and 63.8% per annum respectively while EPS is expected to grow by 33.9% per annum.
Key information
25.7%
Earnings growth rate
29.8%
EPS growth rate
| Biotechs earnings growth | 24.4% |
| Revenue growth rate | 59.1% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 07 May 2024 |
Recent future growth updates
Recent updates
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Feb 29Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17Avidity slips 20% as FDA places lead asset on partial clinical hold
Sep 27We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29Avidity stock rises amid Chardan starting coverage with Buy
Jul 20Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides
Jul 12We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
Mar 26Avidity Biosciences: Risks And Potential
Dec 09We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Nov 30Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans
Jun 07Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth
Feb 22Avidity Biosciences Has A Promising RNA Therapy Platform
Jan 13Avidity inks research deal with Bristol Myers' subsidiary, gives 2021 pipeline updates
Jan 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 85 | -301 | -215 | -138 | 4 |
| 12/31/2025 | 11 | -316 | -259 | -226 | 6 |
| 12/31/2024 | 13 | -270 | -233 | -213 | 7 |
| 12/31/2023 | 10 | -212 | -123 | -119 | N/A |
| 9/30/2023 | 10 | -202 | -179 | -175 | N/A |
| 6/30/2023 | 10 | -193 | -173 | -170 | N/A |
| 3/31/2023 | 10 | -192 | -160 | -156 | N/A |
| 12/31/2022 | 9 | -174 | -139 | -136 | N/A |
| 9/30/2022 | 8 | -162 | -127 | -123 | N/A |
| 6/30/2022 | 8 | -148 | -117 | -112 | N/A |
| 3/31/2022 | 8 | -128 | -109 | -105 | N/A |
| 12/31/2021 | 9 | -118 | -99 | -95 | N/A |
| 9/30/2021 | 10 | -96 | -84 | -82 | N/A |
| 6/30/2021 | 9 | -78 | -72 | -70 | N/A |
| 3/31/2021 | 8 | -62 | -51 | -50 | N/A |
| 12/31/2020 | 7 | -44 | -38 | -37 | N/A |
| 9/30/2020 | 6 | -38 | -30 | -29 | N/A |
| 6/30/2020 | 5 | -34 | -26 | -26 | N/A |
| 3/31/2020 | 4 | -28 | -3 | -3 | N/A |
| 12/31/2019 | 2 | -25 | 2 | 2 | N/A |
| 12/31/2018 | 0 | -11 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RNA's revenue (63.8% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: RNA's revenue (63.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RNA's Return on Equity is forecast to be high in 3 years time